Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Animal & Veterinary

FDA Seeks Comments on Potential Changes to Conditional Approvals for New Animal Drugs

September 8, 2014

The U.S. Food and Drug Administration announced today it is soliciting public comment on expanding the availability of conditional approvals for new animal drugs.

Currently, conditional approvals are only available for new animal drugs that are intended for use in minor species (such as zoo animals) or for minor uses in major species (such as rare diseases in horses, cattle, pigs, dogs, cats, chickens or turkeys). A conditional approval allows a drug manufacturer to market its new animal drug before submitting the effectiveness data necessary for a full approval, but after proving the drug is safe in accordance with the full FDA approval standard and showing that there is a reasonable expectation of effectiveness.

The FDA is considering expanding the use of conditional approval in accordance with Animal Drug User Fee Amendments of 2013 (ADUFA III) performance goals. ADUFA III authorizes the FDA to collect user fees from animal drug sponsors to expedite and modernize the animal drug review processing exchange for FDA agreeing to meet a comprehensive set of performance goals to show significant improvement in the timeliness and predictability of the new animal drug review process. The FDA invites public comment as the agency explores this change.

The FDA is accepting public comments beginning on September 9, 2014. To submit your comments electronically to the docket, go to and type FDA-2014-N-1049 in the search box. Please note that the docket will not be open to accept comments until this date. The comment period will close on March 9, 2015. While comments are welcome at any time, you should submit them by the closing date in order for your comments to be considered in drafting recommendations by September 30, 2015 in accordance with the ADUFA III performance goals.

To submit your comments to the docket by mail, use the following address. Be sure to include docket number FDA-2014-N-1049 on each page of your written comments.

Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Additional Information

Contact FDA

240-276-9115 FAX
Issued by: FDA, Center for Veterinary Medicine

7519 Standish Place, HFV-1

Rockville, MD 20855

Page Last Updated: 01/25/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English